uploads///SGMO net loss

How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

By

Jan. 2 2019, Updated 4:00 p.m. ET

Earnings trends

In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year. The company reported EPS of -$0.52 in this period compared to -$0.55 in the first nine months of 2017. Wall Street analysts estimate that the company will report net income and EPS of -$68.63 million and -$0.73, respectively, in fiscal 2018.

In the third quarter, Sangamo Therapeutics reported net income and EPS of -$12.8 million and -$0.13, respectively, compared to -$12.4 million and -$0.15 in the third quarter of 2017.

Analysts estimate that the company is expected to report net income and EPS of -$17.47 and -$0.19, respectively, in the fourth quarter of 2018.

Article continues below advertisement

Peers’ performance

Sangamo Therapeutics’ peers in the biopharmaceuticals market, Spark Therapeutics (ONCE), Amicus Therapeutics (FOLD), and bluebird bio (BLUE) reported net income of -$47.36 million, -$159.2 million, and -$145.5 million, respectively, in the third quarter of 2018.

Expense trends

In the first nine months of 2018, Sangamo Therapeutics reported R&D (research and development) and G&A (general and administrative) expenses of $81.6 million and $32.4 million, respectively, compared to $46.4 million and $19.7 million in the same period the prior year.

In the third quarter, the company reported R&D and G&A expenditure of $28.8 million and $11.0 million, respectively, compared to $18.4 million and $6.4 million in the same period the prior year.

Wall Street analysts estimate that in the fourth quarter, Sangamo Therapeutics will report R&D and G&A expenses of $31.05 million and $12.73 million, respectively. Analysts also estimate that the company is expected to report R&D and G&A expenses of $112.18 million and $45.12 million, respectively, in fiscal 2018.

Advertisement

More From Market Realist

  • BioNano Genomics Saphyr system
    Company & Industry Overviews
    BioNano Genomics (BNGO) Stock Looks Like a Buy, Solid Opportunity
  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.